Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Thrombate infusion · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Thrombate infusion | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Thrombate infusion | DRUG | Bolus intravenous infusion of Thrombate will be given to achieve antithrombin (AT) activity levels at 150% before the 3rd dose of Enoxaparin. The dose will be based on patient weight. |
| Placebo | DRUG | Normal Saline will be given as one time IV before the 3rd dose of Enoxaparin. The dose will be based on patient weight. |
Inclusion Criteria: * Admission to trauma service * Polytraumatic injuries OR pelvic/long bone fracture * Planned admission to trauma ICU or step-down/SIMU setting (this includes STICU, SIMU/TIMU, BICU, and BIMU) * Informed consent obtained Exclusion Criteria: * Prisoners (defined as those direct...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| CytoSorbents Corporation | CTSO | 1 | - | Undisclosed |
| Bone Biologics Corp. | BBLG | 1 | - | Undisclosed |
Thrombate infusion is an investigational small molecule being studied for trauma injury. It is being evaluated to improve thromboprophylaxis and reduce the incidence of trauma-related venous thromboembolism. The drug is currently in Phase 2 clinical development and is not yet approved by the FDA.
Thrombate infusion targets antithrombin III, a protein that helps regulate blood clotting. By acting on this target, the drug is intended to improve thromboprophylaxis and reduce the risk of venous thromboembolism in patients with trauma injury.
Thrombate infusion is being developed by Grifols, S.A., a biopharmaceutical company. Grifols is publicly traded under the ticker symbol GRFS. The drug is currently in Phase 2 clinical trials for trauma injury.
Thrombate infusion is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 2 trial is enrolling patients by invitation and is designed to assess the drug's efficacy in reducing trauma-related venous thromboembolism.
Thrombate infusion is being studied in one active Phase 2 clinical trial with the identifier NCT05794165. This randomized, double-blind, placebo-controlled trial is enrolling 314 participants in the United States. The trial is investigating the drug's ability to improve thromboprophylaxis and reduce trauma-related venous thromboembolism.
Thrombate infusion targets antithrombin III, but it is not the same as antithrombin III itself. The drug is designed to act on antithrombin III to enhance its anticoagulant effects. This mechanism is being studied for its potential to prevent venous thromboembolism in trauma patients.